Table 1.
Univariate and Multivariate analysis of risk factors and OS in TCGA.
| Variables | HR (95% CI) | p-Value |
|---|---|---|
| Univariate analysis | ||
| NR2F1 (low vs. high) | 1.486 (1.145–1.929) | 0.003 |
| FIGO stage (Stage I&Stage II vs. Stage III&Stage IV) | 2.115 (0.938–4.766) | 0.071 |
| Primary therapy outcome (PD&SD vs. PR&CR) | 0.301 (0.204–0.444) | <0.001 |
| Race (Asian vs. Black or African American) | 1.302 (0.437–3.882) | 0.636 |
| Race (Asian vs. White) | 0.785 (0.290–2.127) | 0.634 |
| Age (≤60 years vs. >60 years) | 1.355 (1.046–1.754) | 0.021 |
| Histologic grade (G1&G2 vs. G3&G4) | 1.229 (0.830–1.818) | 0.303 |
| Anatomic neoplasm subdivision (Bilateral vs. Unilateral) | 0.953 (0.705–1.289) | 0.757 |
| Venous invasion (No vs. Yes) | 0.896 (0.487–1.649) | 0.723 |
| Lymphatic invasion (No vs. Yes) | 1.413 (0.833–2.396) | 0.200 |
| Tumor residual (NRD vs. RD) | 2.313 (1.486–3.599) | <0.001 |
| Multivariate analysis | ||
| NR2F1 (low vs. high) | 1.439 (1.054–1.963) | 0.022 |
| Primary therapy outcome (PD&SD vs. PR&CR) | 0.287 (0.189–0.435) | <0.001 |
| Tumor residual (NRD vs. RD) | 2.301 (1.390–3.810) | 0.001 |
HR, hazard ratio; CI, confidence interval; OS, overall survival; FIGO, Federation International of Gynecology and Obstetrics; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; RD, recurrent disease; NRD, on-recurrent disease.